홈 › 급성 골수성 백혈병 › 인디애나
인디애나의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 14개가 인디애나 내 여러 지역에서 참여자를 모집하고 있습니다.
인디애나의 도시
공식 연구 텍스트(영어)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- UChicago Medicine Northwest Indiana, Crown Point
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- UChicago Medicine Northwest Indiana, Crown Point
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT05554406Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- UChicago Medicine Northwest Indiana, Crown Point
피험자 모집 중2상
60세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05334069MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT05564390Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- UChicago Medicine Northwest Indiana, Crown Point
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- UChicago Medicine Northwest Indiana, Crown Point
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06672146A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Riley Hospital for Children, Indianapolis
피험자 모집 중1상
21세 이하 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT07012044Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Clinical Trial Site, Indianapolis
피험자 모집 중3상
12세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07211958A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Riley Hospital for Children, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
피험자 모집 중3상
6 Months – 21 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Riley Hospital for Children, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Indiana University/Riley Hospital for Children, Indianapolis
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Community Health Network, Indianapolis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 24. 업데이트됨 · NCT04068597Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Indiana University, Bloomington
피험자 모집 중건강한 지원자 환영
18세 ~ 120세 · 모든 성별 · 2025. 7. 25. 업데이트됨 · NCT05237258ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.